Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Prostatic Neoplasms 86Breast Neoplasms 15Neoplasms 6Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Salivary Gland Neoplasms 2Prostate Adenocarcinoma 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leiomyoma 2Hodgkin Disease 2Uveal Melanoma 1Uterine Neoplasms 1Urogenital Neoplasms 1Skin Neoplasms 1Skin Diseases 1Salivary Gland Neoplasm Duct 1Recurrence 1Rare Diseases 1Prostatic Diseases 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1PSA Level Greater Than Two 1Obesity, Morbid 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms, Glandular and Epithelial 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Melanoma 1Lymphoma, Mantle-Cell 1

Interventions

montanide ISA 51 1binimetinib 1belinostat 1Proton Therapy 1Peptides 1Melphalan 1MART-1 Antigen 1MAGEA3 protein, human 1Leuprolide 1Lasers 1Laparotomy 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Eye Neoplasms × Leuprolide × Clear all
NCT00254397 2019-10-16

Melanoma Vaccine With Peptides and Leuprolide

M.D. Anderson Cancer Center

Phase 2 Completed
98 enrolled 11 charts
Dermatologic

Uveal Melanoma, Eye Neoplasms, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡